ODD request is a routine regulatory step for a pre-revenue biotech — not a binary catalyst. Watch for ODD grant, which could provide incentives and modest upside, and for the WCP 2026 presentation next week. The limited cash runway (~$9M) remains the primary risk.
Price Chart
Executive Summary
SL Science has submitted an Orphan Drug Designation (ODD) request to the FDA for its GDT cell therapy targeting glioblastoma. The FDA has acknowledged receipt, but the designation has not been granted yet. This is an early regulatory milestone for a pre-revenue biotech, and while the filing is directionally positive, ODD submission alone does not move the stock meaningfully.
Key Facts
- SL Science submitted an ODD request to the FDA for Vdelta2+ Gamma Delta T Cells treating glioblastoma.
- FDA's OOPD formally acknowledged receipt on March 30, 2026.
- ODD is not yet granted — submission is a request, not an approval.
- JY BioMed, the licensor of the GDT technology, will present preclinical GBM data at WCP 2026 July 12-17.
- Company is pre-revenue with a net loss of $3.8M in 2025, ~$9M pro forma cash, and no FDA IND filed yet.
- The 20-F cross-filing (June 18, 2026) shows the company remains early-stage with limited runway.
Financial Impact
No financial metrics reported in this filing. ODD request has no direct revenue impact.
Risk Factors
- ODD may not be granted; no guarantee of designation.
- Company is pre-revenue with no clinical-stage assets — IND filings not expected until at least 2027.
- Limited cash runway of ~$9M per the 20-F may require near-term financing, diluting shareholders.
- GDT cell therapy is preclinical for GBM — no human data yet; failure risk is high.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (SLBT) — Batch item 1 | 0001104659-26-082459 |
| Document: tm2620209d1_6k.htm | 0001104659-26-082459 |
| Document: 0001104659-26-082459-index-headers.html | 0001104659-26-082459 |
| Document: 0001104659-26-082459-index.html | 0001104659-26-082459 |
| Document: 0001104659-26-082459.txt | 0001104659-26-082459 |
| 6-K Filing (SLBT) — Batch item 6 | 0001104659-26-082459 |
| Document: tm2620209d1_6k.htm | 0001104659-26-082459 |
| Document: 0001104659-26-082459-index-headers.html | 0001104659-26-082459 |
| Document: 0001104659-26-082459-index.html | 0001104659-26-082459 |
| Document: 0001104659-26-082459.txt | 0001104659-26-082459 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.24 | awaiting T+20 | — | $1.23 (−0.81%) |
Oct 26, 2026 1d ago | Press Release | $1.24 | awaiting T+20 | — | $1.23 (−0.81%) |
Oct 1, 2026 26d ago | SC 13D/A | $1.57 | awaiting T+20 | — | $1.23 (−21.66%) |
Aug 13, 2026 10w ago | EFFECT | $2.71 $2.06 | ▼ −23.99% | ▼ −22.24% | $1.23 (−54.61%) |
Jul 31, 2026 12w ago | F-1 | $3.29 $2.73 | ▼ −17.02% | ▼ −18.26% | $1.23 (−62.61%) |
Jul 10, 2026 15w ago | 6-K | $4.73 $2.67 | ▼ −43.55% | ▼ −45.98% | $1.23 (−74.00%) |
Jun 18, 2026 18w ago | 20-F | $4.52 $4.30 | ▼ −4.87% | ▼ −4.72% | $1.23 (−72.79%) |
Jun 17, 2026 18w ago | 3 | $6.38 $4.33 | ▼ −32.13% | ▼ −33.45% | $1.23 (−80.72%) |
Jun 15, 2026 19w ago | 3 | $3.33 $4.33 | ▲ +30.03% | ▲ +30.78% | $1.23 (−63.06%) |
Jun 15, 2026 19w ago | 6-K | $3.33 $4.33 | ▲ +30.03% | ▲ +30.78% | $1.23 (−63.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers